UA102087C2 - 3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6receptors, methods for the production and the use thereof - Google Patents

3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6receptors, methods for the production and the use thereof

Info

Publication number
UA102087C2
UA102087C2 UAA201009958A UAA201009958A UA102087C2 UA 102087 C2 UA102087 C2 UA 102087C2 UA A201009958 A UAA201009958 A UA A201009958A UA A201009958 A UAA201009958 A UA A201009958A UA 102087 C2 UA102087 C2 UA 102087C2
Authority
UA
Ukraine
Prior art keywords
serotonin
optionally substituted
novel
pyrazolo
pyrimidines
Prior art date
Application number
UAA201009958A
Other languages
English (en)
Ukrainian (uk)
Inventor
Андрей Александрович Иващенко
Александр Васильевич Иващенко
Николай Филиппович Савчук
Original Assignee
Общество С Ограниченной Ответственностью "Инновационная Фармацевтика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Инновационная Фармацевтика" filed Critical Общество С Ограниченной Ответственностью "Инновационная Фармацевтика"
Publication of UA102087C2 publication Critical patent/UA102087C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Данное изобретение касается 3-арилсульфонил-пиразоло[1,5-а]пиримидинов общей формулы 1 или их фармацевтически приемлемых солей и/или гидратов, антагонистов серотониновых 5-НТрецепторов, лекарственных субстанций, фармацевтических композиций, лекарственных препаратов и способов их получения и применения для лечения и предупреждения патологических состояний и заболеваний ЦНС, патогенез которых связан с нарушением активации серотониновых 5-НТрецепторов.В соединениях общей формулы 1(1)Ar является необязательно замещенным арилом или необязательно замещенным гетероциклилом; R, Ri Rнезависимо друг от друга являются атомом водорода, C-Салкилом или фенилом; Rявляется атомом водорода, необязательно замещенным С-Салкилом, замещенной гидроксильной группой или замещенной сульфонильной группой.
UAA201009958A 2008-01-24 2009-01-23 3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6receptors, methods for the production and the use thereof UA102087C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2008102154/04A RU2369600C1 (ru) 2008-01-24 2008-01-24 ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
PCT/IB2009/050270 WO2009093206A2 (ru) 2008-01-24 2009-01-23 3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Publications (1)

Publication Number Publication Date
UA102087C2 true UA102087C2 (en) 2013-06-10

Family

ID=40901496

Family Applications (4)

Application Number Title Priority Date Filing Date
UAA201009961A UA100138C2 (ru) 2008-01-24 2009-01-23 ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e АБО d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
UAA201009960A UA101643C2 (en) 2008-01-24 2009-01-23 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO[1,5-A]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, PROCESS FOR THE PREPARATION AND USE THEREOF
UAA201009959A UA100137C2 (en) 2008-01-24 2009-01-23 SUBSTITUTED 2-AMINO-3-SULFONYL-PYRAZOLO[1,5-a]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND USE THEREOF
UAA201009958A UA102087C2 (en) 2008-01-24 2009-01-23 3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6receptors, methods for the production and the use thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
UAA201009961A UA100138C2 (ru) 2008-01-24 2009-01-23 ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e АБО d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
UAA201009960A UA101643C2 (en) 2008-01-24 2009-01-23 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO[1,5-A]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, PROCESS FOR THE PREPARATION AND USE THEREOF
UAA201009959A UA100137C2 (en) 2008-01-24 2009-01-23 SUBSTITUTED 2-AMINO-3-SULFONYL-PYRAZOLO[1,5-a]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND USE THEREOF

Country Status (10)

Country Link
US (1) US8552005B2 (ru)
EP (1) EP2248815B1 (ru)
JP (1) JP5690594B2 (ru)
KR (1) KR101526930B1 (ru)
CA (1) CA2749742C (ru)
DK (1) DK2248815T3 (ru)
EA (1) EA017817B1 (ru)
RU (1) RU2369600C1 (ru)
UA (4) UA100138C2 (ru)
WO (1) WO2009093206A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110069148A (ko) * 2008-10-06 2011-06-22 알라 캠, 엘엘씨 치환된 3-아릴설포닐-피라졸로［1,5-ａ］피리미딘, 세로토닌 5-ＨＴ6 수용체의 길항제, 물질의 제조방법 및 이의 용도
US10864191B2 (en) 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
WO2018050825A1 (de) * 2016-09-19 2018-03-22 Bayer Cropscience Aktiengesellschaft Pyrazolo[1,5-a]pyridin- derivative und ihre verwendung als schädlingsbekämpfungsmittel
MX385719B (es) 2017-05-24 2025-03-18 H Lundbeck As Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531485D0 (en) * 1985-12-20 1986-02-05 May & Baker Ltd Compositions of matter
JPH09143181A (ja) * 1995-09-22 1997-06-03 Takeda Chem Ind Ltd 新規トリアゾール系化合物、その製造法、中間体および農薬
AU7001396A (en) * 1995-09-22 1997-04-09 Takeda Chemical Industries Ltd. Triazole compounds, their production and use
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
EP1212304A2 (en) * 1999-08-27 2002-06-12 Eli Lilly And Company Hypoglycemic sulfonyl pyrazolones and pyrazolines
DE60130924T2 (de) * 2000-12-28 2008-07-17 Ono Pharmaceutical Co. Ltd. Cyclopentaädüpyrazoloä1,5-aüpyrimidin-verbindung als crf-rezeptor antagonist
EP1368355B1 (de) * 2001-03-14 2006-06-07 Grünenthal GmbH Substituierte pyrazolo- und thiazolopyrimidine als analgetika
EP1465872A1 (en) 2001-12-28 2004-10-13 Bayer Pharmaceuticals Corporation 4-sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
JP2005527542A (ja) * 2002-03-27 2005-09-15 グラクソ　グループ　リミテッド キノリンおよびアザインドール誘導体およびその５−ｈｔ６リガンドとしての使用
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
AU2006305104B2 (en) * 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
EP2248815A4 (en) 2012-02-15
EP2248815A2 (en) 2010-11-10
UA101643C2 (en) 2013-04-25
EP2248815B1 (en) 2014-09-24
KR20100137428A (ko) 2010-12-30
EA201001179A1 (ru) 2011-02-28
CA2749742C (en) 2016-04-26
US20100331347A1 (en) 2010-12-30
RU2369600C1 (ru) 2009-10-10
CA2749742A1 (en) 2009-07-30
WO2009093206A2 (ru) 2009-07-30
KR101526930B1 (ko) 2015-06-08
JP2011510061A (ja) 2011-03-31
EA017817B1 (ru) 2013-03-29
RU2008102154A (ru) 2009-07-27
UA100138C2 (ru) 2012-11-26
UA100137C2 (en) 2012-11-26
US8552005B2 (en) 2013-10-08
WO2009093206A3 (ru) 2009-10-29
JP5690594B2 (ja) 2015-03-25
DK2248815T3 (en) 2014-11-17

Similar Documents

Publication Publication Date Title
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2011009796A (es) Inhibidores de la cinasa pi3.
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
SI2150530T1 (sl) Substituirani sulfonamidni derivati
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
PH12013501557A1 (en) Glucagon receptor modulator
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2012048129A3 (en) Inhibitors of polo-like kinase
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
WO2012131656A3 (en) Compounds for use as therapeutic agents affecting p53 expression and/or activity
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MX2013006768A (es) Moduladores de receptor de glucagon.